Agomelatine Monotherapy for Autism-A Case Report.

Q3 Medicine Psychopharmacology bulletin Pub Date : 2022-10-27
Ahmed Naguy, Saxby Pridmore, Mohammed A Jamali, Alaa Eisa Hasan, Bibi Alamiri
{"title":"Agomelatine Monotherapy for Autism-A Case Report.","authors":"Ahmed Naguy,&nbsp;Saxby Pridmore,&nbsp;Mohammed A Jamali,&nbsp;Alaa Eisa Hasan,&nbsp;Bibi Alamiri","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>ASD is commonly associated with a host of challenging behaviours. Pharmacotherapy is indicated if psycho-social and educational interventions fail. Atypical antipsychotics have the strongest evidence-base so far, with both risperidone and aripiprazole are FDA-approved. Unfortunately, their use is fraught with metabolic and neuro-hormonal side effects. Here, authors report on a case of ASD/mild ID with behavioural dyscontrol that failed multiple psychotropic trials and ultimately responded favourably to agomelatine monotherapy. This was achieved with excellent tolerability. This might open new venues in such complicated cases.</p>","PeriodicalId":21069,"journal":{"name":"Psychopharmacology bulletin","volume":"52 4","pages":"100-103"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611798/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

ASD is commonly associated with a host of challenging behaviours. Pharmacotherapy is indicated if psycho-social and educational interventions fail. Atypical antipsychotics have the strongest evidence-base so far, with both risperidone and aripiprazole are FDA-approved. Unfortunately, their use is fraught with metabolic and neuro-hormonal side effects. Here, authors report on a case of ASD/mild ID with behavioural dyscontrol that failed multiple psychotropic trials and ultimately responded favourably to agomelatine monotherapy. This was achieved with excellent tolerability. This might open new venues in such complicated cases.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
阿戈美拉汀单药治疗自闭症一例报告。
ASD通常与一系列具有挑战性的行为有关。如果心理社会和教育干预失败,则需要药物治疗。到目前为止,非典型抗精神病药物有最有力的证据基础,利培酮和阿立哌唑都获得了美国食品药品监督管理局的批准。不幸的是,它们的使用充满了代谢和神经激素的副作用。在此,作者报告了一例ASD/轻度ID伴行为控制障碍的病例,该病例未通过多项精神试验,最终对阿戈美拉汀单药治疗反应良好。这是在良好的耐受性下实现的。在这种复杂的情况下,这可能会开辟新的场地。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Psychopharmacology bulletin
Psychopharmacology bulletin PHARMACOLOGY & PHARMACY-PSYCHIATRY
CiteScore
2.70
自引率
0.00%
发文量
32
期刊介绍: Information not localized
期刊最新文献
Takotsubo Cardiomyopathy Related to Duloxetine-Atomoxetine Combination in an Adolescent with ADHD and Comorbid GAD. On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression. Alzheimer's and Dementia Guidelines and Tables. Captagone & Morbid Jealousy. Are Standardized Tests Sensitive to Early Cognitive Change in Parkinson's Disease?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1